Home > Press > BioDevice Partnering 2007, Zurich, Switzerland – June 12-13, 2007, First Call to Journalists
EBD Group (The leading partnering firm for the Life Science Industry) - and Eucomed (The Voice of the Medical Technology Industry in Europe) are pleased to announce the upcoming BioDevice Partnering 2007.
BioDevice Partnering 2007, Zurich, Switzerland – June 12-13, 2007, First Call to Journalists
CARLSBAD, CA & BRUSSELS, Belgium | Posted on February 19th, 2007
BioDevice Partnering will take place in Zurich, Switzerland, June 12-13, 2007. The conference provides an interdisciplinary forum where international decision makers from the various healthcare industries can meet to initiate or develop cross-sector partnerships between their companies.
This second edition of BioDevice Partnering will strengthen the use of organized partnering in the innovative areas of the medtech industry, particularly where there is convergence with biotech / pharma. The event will also explore links with other exciting technologies that are converging into the medical device space such as tissue regeneration, biomaterials and nanotechnology.
The success of the first edition of BioDevice Partnering in June 2006 in Edinburgh, Scotland, exceeded all expectations with 330 attendees from 214 companies representing 21 countries and confirms BioDevice Partnering as the largest international drug-device combination event.
BioDevice Partnering 2007 will include presentations by innovative companies from Europe and beyond aiming to attract leading medical device and pharmaceutical corporations, and investment companies, as potential clients and partners.
In addition to plenary sessions and panel discussions featuring industry leaders, company presentations and informal networking opportunities, the event will offer EBD's fully searchable web-based partnering system which will allow delegates to select potential partners and pre-schedule one-on-one meetings in private booths.
The event is sponsored by firms from the medical device, pharmaceutical, biotech, finance, legal, consulting and publishing industries. More information will become available over the coming weeks and we invite you to check regularly the conference website at http://www.biodevice-partnering.com.
Entry to BioDevice Partnering 2007 is, as for other EBD conferences, free to media, giving full access to all sessions and the ability to request partnering meetings. Attending journalists will also receive a complimentary delegate pack, including the complete conference handbook.
Please visit the BioDevice Partnering 2007 conference website at http://www.biodevice-partnering.com for detailed information on the event and online registration.
If you are interested in attending the conference, or require further information, please contact: Sabina Stampanoni, EBD Group, Inc., Phone: +1 760 239 1291, Email: .
About EBD Group
EBD Group is the leading partnering firm for the global biotechnology industry. For over 12 years, firms in the life sciences have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships that drive their business. EBD Group’s conferences (run in collaboration with leading industry partners and international trade associations such as BIO and Eucomed) include: BIO-Europe, the world’s largest stand-alone life science partnering conference; BIO-Europe Spring; BioEquity Europe, an investor conference co-organized with BioCentury Publications; and BioDevice Partnering, a convergent medical technology partnering conference. EBD’s proprietary software system also powers partnering at numerous third-party events around the world. Outside of the conference format, EBD Group’s consultants provide hands-on operational consulting for firms seeking to in- or out license products and technologies.
EBD Group has offices in San Diego, Munich and London. For more information visit http://www.ebdgroup.com or http://www.biodevice-partnering.com for conference related issues.
Eucomed is the voice of the medical technology industry in Europe. Eucomed represents directly and indirectly 4500 designers, manufacturers and suppliers of medical technology used in the diagnosis, prevention, treatment and amelioration of disease and disability. Small and medium size companies make up more than 80% of this sector. The European medical technology industry invests some EUR 3,7 billion in R&D and employs near to 445.000 highly skilled workers. The mission of Eucomed is to improve patient and clinician access to modern, innovative and reliable medical technology. Visit our website at http://www.eucomed.org .
For more information, please click here
EBD Group, Inc.
Sabina Stampanoni, +1 760 239 1291
Copyright © Business Wire
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Carbon Nanotubes Market by Type (SWCNTS & MWCNTS), Application (Electronics, Chemicals, Energy, Medical, Composites, Aerospace & more) & Geography - Global Trends & Forecasts To 2018 March 9th, 2014
Toxicity of Commonly-Used Nanoparticles on Human Body Studied in Iran March 9th, 2014
Aptasensors Help Detection of Cancer Protein Marker March 9th, 2014
Nano Labs Shareholder Update March 8th, 2014
Singapore's A*STAR IME will present 9 papers in optical device innovation and foundry-qualified platform development at world-class optical communications conference March 6th, 2014
How 19th Century Physics Could Change the Future of Nanotechnology: University of Cincinnati physics researchers have developed a new way of using an old technique that could help build better nanotechnology March 5th, 2014
Malvern Instruments announces guest presenter for March 18th protein characterization webinar: Renowned protein scientist Prof. Dr. John F. Carpenter shows how combining Dynamic Light Scattering with Raman Spectroscopy delivers new insights in protein stability, aggregation... March 4th, 2014
UC research tests which nano system works best in killing cancer cells: New UC research to be presented this week tested four iron-oxide nanoparticle systems to see which, when heated, would likely work best as a tool for targeting cancer cells March 4th, 2014